Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias

Long-term Follow-up of Sclerotherapy of Reticular Veins and Telangiectasias

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05860439

Enrollment

191

Registered

2023-05-16

Start date

2017-01-01

Completion date

2023-06-01

Last updated

2023-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telangiectasis

Keywords

Sclerotherapy, Veins, Telangiectasias, Hyperpigmentation

Brief summary

A long-term follow-up cohort study of patients that were assigned in two previous studies to compare the clinical results of sclerotherapy of telangiectasias and reticular veins of lower limbs using 0.2% polidocanol diluted in 70% hypertonic glucose (PDHG) vs 75% hypertonic glucose (HG) alone. All women, previously treated as aforementioned, were invited to be reevaluated regarding late maintenance and pigmentation over two years of follow-up. No new treatments were applied to the cohort.

Interventions

PROCEDUREPolidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Patients previously treated were reassessed for long-term follow-up.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* All patients that concluded the participation of 60 days in both primary studies were invited to reevaluate the actual status of treatment (maintenance of treated vessels) and late complications (pigmentation and matting).

Exclusion criteria

* Patients who did not agree to be reassessed; * Patients who were not found after all available forms of contact had been tried; * Patients who went through any kind of intervention on the area of interest in lower limbs between the end of the intervention and the reevaluation for long-term follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Length of Telangiectasias in Centimeters	730 days	Total length of telangiectasias at day 730 for comparison with day 60 and assessment of disease relapse.

Secondary

Measure	Time frame	Description
Length of Hyperchromia in Centimeters	730 days	Total length of hyperchromic stains at day 730 for comparison with day 60 and assessment of reversion.
Length of Matting in Centimeters	730 days	Total length of matting neovascularization at day 730 for comparison with day 60 and assessment of reversion.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026